Brilliant Violet 605™ anti-mouse IL-33Rα (IL1RL1, ST2)

Antibodies Single
Sony
DIH9
Flow Cytometry
Rat IgG2a, κ
Mouse
IL-33Rα-hFcγ1 fusion protein.
50 µg
1326615
CHF274.00

Description

IL-33Rα, also known as ST2 or IL-1RL1, is a member of the Toll/IL-1 receptor family.  It binds IL-33 and is structurally similar to IL-1R1.  Two forms of the protein exist - a soluble form known as ST2 and a membrane anchored form known as ST2L.  The membrane form is expressed by Th2 cells and bone marrow derived mast cells, whereas the soluble form is expressed by serum-stimulated fibroblasts.

Blocking with anti-ST2 antibodies has been shown to alleviate experimental arthritis and airway inflammation.  The IL-33-ST2 axis has been reported to be important across a range of diseases including asthma, allergies, and cardiac disease.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

  1. Hashiguchi M, et al. 2014. Eur. J. Immunology. (FC) PubMed